The divide between Eli Lilly and Novo Nordisk is widening after their latest earnings
As Lilly widens its lead in the obesity race, Novo is still racing to win back market share and restore investor confidence in its pipeline.
This is a summary aggregated from CNBC. Read the complete article on the original site:
Read full article at CNBC
